Gilead Launches New Study To Evaluate Lenacapavir In HIV Prevention As Part Of PURPOSE Program
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – Gilead Sciences, Inc. (GILD) Wednesday said it launched PURPOSE 5, the company’s Phase 2 study to evaluate lenacapavir as long-acting HIV prevention option.
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1412762529-2fb014f1b6534c44bc40e451aad3e66c.jpg "<div>Accounting vs. Auditing: What's the Difference?</div>")
